ProQR stock rating reiterated at Market Outperform by Citizens

Investing.com - Citizens has reiterated its Market Outperform rating and $8.00 price target on ProQR Therapeutics N.V. (NASDAQ:PRQR), according to a research note published Wednesday. Trading at $2.46, the $259M market cap company has received strong analyst support, with consensus targets ranging from $4.03 to $14.00, according to InvestingPro data.

Citizens analyst Jonathan Wolleben maintained the rating based on a risk-adjusted, sum-of-the-parts analysis of the RNA technology company.

The firm announced it will host an investor dinner in New York on Monday, October 20, 2025, featuring ProQR’s recently hired CFO Dennis Hom and VP of IR and Corporate Affairs Sarah Kiely.

ProQR is developing a next-generation RNA technology called Axiomer, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse mutations or modulate protein expression.

The Axiomer platform has been validated through ProQR’s partnership with Eli Lilly, which was expanded in 2022 and is valued at up to $3.9 billion.

In other recent news, Cantor Fitzgerald has maintained its Overweight rating on ProQR Therapeutics N.V., with a price target set at $8.00. This decision follows a series of virtual investor meetings involving the company’s key leadership, including CEO Daniel de Boer, CFO Dennis Hom, and CMO Cristina Lopez Lopez. The meetings also featured Sarah Kiely from investor relations. Cantor Fitzgerald’s reiterated rating suggests continued confidence in ProQR’s future prospects, particularly as the company approaches key data releases in the second half of 2025. These developments highlight ongoing interest and analysis from financial institutions regarding ProQR’s strategic direction and potential market performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.